Fernando Goldzstein e seu filho – Foto: X
A Brazilian father turned his fight to save his son into a global mission, revolutionizing medulloblastoma treatment, a rare brain cancer affecting children. Fernando Goldzstein founded the Medulloblastoma Initiative (MBI), leading to two experimental therapies approved in the U.S. within four years. These breakthroughs, now in clinical trials, promise less toxic treatments. The initiative’s impact is set to reach Brazil, offering hope to patients.
- Innovative therapies: Target only tumor cells, reducing side effects.
- Rapid approval: FDA greenlit trials in record time.
- Global reach: Research to benefit Brazilian patients by 2026.
Breakthrough in medulloblastoma treatment
The MBI, led by Fernando, united 28 scientists across 16 labs in the U.S., Canada, and Germany. The approved therapies use the body’s cells to attack tumors. They also reprogram the immune system, minimizing long-term damage.
A father’s relentless fight
Frederico, diagnosed at 9, underwent surgery, chemo, and radiation. The standard protocol, unchanged for 40 years, often causes permanent side effects. When the cancer returned, Fernando rejected the grim prognosis. He partnered with Dr. Roger Packer, a global expert in medulloblastoma. Their collaboration yielded therapies now tested in U.S. children.
Impact reaches Brazil
Starting in 2026, Hospital Albert Einstein will access MBI’s research results. This will enable clinical trials in Brazil, expanding access to new treatments. The therapies prioritize lower toxicity, preserving patients’ quality of life. Frederico, now 19, remains in treatment, inspiring the ongoing mission.
Global scientific collaboration
Fernando funded the MBI with personal resources, fostering international partnerships. The initiative accelerated research, delivering results in just four years.
Hope for a cure
The personalized therapies offer a path to curing medulloblastoma without severe side effects. Fernando’s work aims to make the disease manageable, saving countless lives.
